(ACR) Acres Commercial Realty - Ratings and Ratios
Mortgage Loans, Mezzanine Financing, Preferred Equity, CRE Equity
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 34.0% |
| Value at Risk 5%th | 49.2% |
| Relative Tail Risk | -12.05% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.97 |
| Alpha | 26.05 |
| CAGR/Max DD | 1.26 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.574 |
| Beta | 0.709 |
| Beta Downside | 0.950 |
| Drawdowns 3y | |
|---|---|
| Max DD | 30.10% |
| Mean DD | 9.65% |
| Median DD | 8.51% |
Description: ACR Acres Commercial Realty December 12, 2025
Acres Commercial Realty Corp. (NYSE: ACR) is a REIT that originates, holds, and manages a diversified portfolio of commercial real-estate mortgage loans and equity investments across the United States. Its product set spans floating-rate first-mortgage loans, first-priority and subordinated interests in those loans, mezzanine financing, preferred equity, and direct CRE equity stakes.
Because ACR meets the REIT qualification, it avoids federal corporate income tax provided it distributes at least 90 % of its taxable earnings to shareholders each year. The firm, incorporated in 2005 and headquartered in Uniondale, NY, rebranded from Exantas Capital Corp. to its current name in February 2021.
Key operating metrics as of the latest filing show a loan-to-value (LTV) ratio near 68 % and a weighted-average loan maturity of roughly 5 years, indicating moderate interest-rate sensitivity. The portfolio is roughly 70 % floating-rate, which historically cushions earnings when the Fed raises rates-a primary sector driver for Mortgage REITs. However, the broader commercial-real-estate market faces headwinds from elevated office vacancy rates and tightening credit spreads, both of which can pressure loan performance and default rates.
For a deeper quantitative breakdown of ACR’s risk profile, you might explore the metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (31.6m TTM) > 0 and > 6% of Revenue (6% = 6.40m TTM) |
| FCFTA -0.00 (>2.0%) and ΔFCFTA -1.49pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 34.57% (prev 43.55%; Δ -8.99pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.00 (>3.0%) and CFO -1.46m <= Net Income 31.6m (YES >=105%, WARN >=100%) |
| Net Debt (-40.9m) to EBITDA (120.0m) ratio: -0.34 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.41 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (7.31m) change vs 12m ago -7.95% (target <= -2.0% for YES) |
| Gross Margin 31.31% (prev 84.93%; Δ -53.62pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 5.77% (prev 8.47%; Δ -2.70pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.30 (EBITDA TTM 120.0m / Interest Expense TTM 89.0m) >= 6 (WARN >= 3) |
Altman Z'' -1.42
| (A) 0.02 = (Total Current Assets 63.0m - Total Current Liabilities 26.2m) / Total Assets 1.69b |
| (B) -0.42 = Retained Earnings (Balance) -717.1m / Total Assets 1.69b |
| (C) 0.06 = EBIT TTM 115.4m / Avg Total Assets 1.85b |
| (D) -0.57 = Book Value of Equity -719.1m / Total Liabilities 1.25b |
| Total Rating: -1.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.17
| 1. Piotroski 4.0pt |
| 2. FCF Yield -0.10% |
| 3. FCF Margin -1.47% |
| 4. Debt/Equity 3.25 |
| 5. Debt/Ebitda -0.34 |
| 6. ROIC - WACC (= 4.53)% |
| 7. RoE 7.31% |
| 8. Rev. Trend 54.47% |
| 9. EPS Trend 0.92% |
What is the price of ACR shares?
Over the past week, the price has changed by +0.81%, over one month by +10.23%, over three months by +14.05% and over the past year by +38.33%.
Is ACR a buy, sell or hold?
- Strong Buy: 0
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ACR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.5 | 3.3% |
| Analysts Target Price | 24.5 | 3.3% |
| ValueRay Target Price | 27.4 | 15.6% |
ACR Fundamental Data Overview December 12, 2025
P/E Trailing = 24.766
P/S = 1.9436
P/B = 0.3945
Beta = 1.218
Revenue TTM = 106.6m USD
EBIT TTM = 115.4m USD
EBITDA TTM = 120.0m USD
Long Term Debt = 1.19b USD (from longTermDebt, last quarter)
Short Term Debt = 131.0m USD (from shortTermDebt, last fiscal year)
Debt = 1.41b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -40.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.54b USD (172.9m + Debt 1.41b - CCE 40.9m)
Interest Coverage Ratio = 1.30 (Ebit TTM 115.4m / Interest Expense TTM 89.0m)
FCF Yield = -0.10% (FCF TTM -1.56m / Enterprise Value 1.54b)
FCF Margin = -1.47% (FCF TTM -1.56m / Revenue TTM 106.6m)
Net Margin = 29.62% (Net Income TTM 31.6m / Revenue TTM 106.6m)
Gross Margin = 31.31% ((Revenue TTM 106.6m - Cost of Revenue TTM 73.2m) / Revenue TTM)
Gross Margin QoQ = 26.53% (prev 38.97%)
Tobins Q-Ratio = 0.91 (Enterprise Value 1.54b / Total Assets 1.69b)
Interest Expense / Debt = 1.42% (Interest Expense 19.9m / Debt 1.41b)
Taxrate = 0.0% (0.0 / 18.0m)
NOPAT = 115.4m (EBIT 115.4m * (1 - 0.00%))
Current Ratio = 2.41 (Total Current Assets 63.0m / Total Current Liabilities 26.2m)
Debt / Equity = 3.25 (Debt 1.41b / totalStockholderEquity, last quarter 432.9m)
Debt / EBITDA = -0.34 (Net Debt -40.9m / EBITDA 120.0m)
Debt / FCF = 26.18 (negative FCF - burning cash) (Net Debt -40.9m / FCF TTM -1.56m)
Total Stockholder Equity = 431.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.87% (Net Income 31.6m / Total Assets 1.69b)
RoE = 7.31% (Net Income TTM 31.6m / Total Stockholder Equity 431.9m)
RoCE = 7.13% (EBIT 115.4m / Capital Employed (Equity 431.9m + L.T.Debt 1.19b))
RoIC = 6.73% (NOPAT 115.4m / Invested Capital 1.71b)
WACC = 2.21% (E(172.9m)/V(1.58b) * Re(8.63%) + D(1.41b)/V(1.58b) * Rd(1.42%) * (1-Tc(0.0)))
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -6.89%
Fair Price DCF = unknown (Cash Flow -1.56m)
EPS Correlation: 0.92 | EPS CAGR: 61.90% | SUE: 1.98 | # QB: 1
Revenue Correlation: 54.47 | Revenue CAGR: 11.98% | SUE: -0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.21 | Chg30d=+0.080 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=1.07 | Chg30d=+0.185 | Revisions Net=+0 | Growth EPS=+1170.0% | Growth Revenue=+0.4%
Additional Sources for ACR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle